Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9001629 | 0.91 | KMT2A (0.62) | KMT2AKDM4EHTTHSD17B2HSD17B1 | |
| SCHEMBL32688152 | 0.89 | KDM1A (0.58) | KMT2AKDM4EHTTHSD17B2L3MBTL1 | |
| SCHEMBL493114 | 0.85 | KMT2A (0.75) | KMT2AKDM4EHTTMAOAKDM1A | |
| SCHEMBL18780858 | 0.84 | KMT2A (0.56) | KMT2AKDM4EHTTHSD17B2HSD17B1 | |
| SCHEMBL29940968 | 0.84 | HSD17B2 (0.72) | KMT2AKDM4EHTTHSD17B2HSD17B1 | |
| SCHEMBL10212283 | 0.84 | HSD17B2 (0.72) | KMT2AKDM4EHTTHSD17B2HSD17B1 | |
| SCHEMBL9229295 | 0.84 | CA12 (0.47) | KMT2AKDM4EL3MBTL1KMO | |
| SCHEMBL9567794 | 0.83 | KMT2A (0.68) | KMT2AKDM4EHTTMAOAATM | |
| SCHEMBL9001650 | 0.83 | MAOA (0.63) | KMT2AKDM4EHTTHSD17B2L3MBTL1 | |
| SCHEMBL1195954 | 0.83 | KMT2A (0.54) | KMT2AKDM4EHTTHSD17B2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099204-A1 | Amide derivative, insecticide containing the same and method for application thereof as insecticide | MITSUI CHEMICALS, INC. (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20090099204-A1 | Amide derivative, insecticide containing the same and method for application thereof as insecticide | MITSUI CHEMICALS, INC. (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20090099204-A1 | Amide derivative, insecticide containing the same and method for application thereof as insecticide | MITSUI CHEMICALS, INC. (JP) | 2009-04-16 | — | — | US | disclosed |
| CN-101203485-A | Amide derivative, pesticide containing such compound and use thereof | MITSUI CHEMICALS INC (JP) | 2008-06-18 | — | — | CN | disclosed |
| EP-1916236-A1 | AMIDE DERIVATIVE, PESTICIDE CONTAINING SUCH COMPOUND AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-1916236-A1 | AMIDE DERIVATIVE, PESTICIDE CONTAINING SUCH COMPOUND AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099204-A1 | Amide derivative, insecticide containing the same and method for application thereof as insecticide | CYP2E1, GSTA1, CYP2S1 | KMT2A 499/4885KDM4E 1117/4885HTT 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.